About polatuzumab vedotin
CD79b-directed antibody-drug conjugate
Used for
- With other medicines for adults with certain types of diffuse large B-cell lymphoma.
- Used in previously untreated or relapsed disease, depending on the treatment combination.
Usual adult dose
1.8 mg/kg by intravenous infusion every 21 days, with a treatment combination; schedule depends on regimen.
Common side effects
- Low blood cell counts
- Nerve damage causing numbness or tingling
- Infections
- Diarrhea, nausea, or tiredness
Important warnings
- Can cause serious infections and dangerously low blood counts.
- Nerve damage may worsen with continued treatment.
- Infusion reactions and tumor lysis syndrome can occur.
- May cause liver problems; monitor blood tests.
Pregnancy
May harm an unborn baby. Avoid pregnancy during treatment and for 3 months after the last dose.
Breastfeeding
Do not breastfeed during treatment or for at least 3 months after the last dose.
Interactions
- Other medicines that cause nerve damage may increase neuropathy risk.
- Strong CYP3A inhibitors or inducers may alter levels of the active drug component.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.